E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Primary or secondary progressive MS |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate neuroregenerative efficacy of autologous mesenchymal stem cell treatment in patients with progressive MS as measured by neurophysiological parameters |
|
E.2.2 | Secondary objectives of the trial |
To investigate neuroregenerative efficacy, safety and feasibilty of autologous mesenchymal stem cell treatment in patients with progressive MS as measured by neurophysiological, radiological, ophtalmological and clinical parameters. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age ≥18 to ≤55, both genders • Diagnosis of secondary progressive or primary progressive MS using revised McDonald criteria of clinically definite MS (1) • An EDSS score of 4 to 7 • Disease duration 2 - 18 years
|
|
E.4 | Principal exclusion criteria |
• Treatment with cytotoxic medications during the last 3 months prior to inclusion • Any illness or prior/ongoing treatment that in the opinion of the investigators would jeopardize the ability of the patient to tolerate autologous stem cell treatment • Any active or chronic infection, including Tbc, CMV, EBV, HSV, VZV, hepatitis virus, toxoplasmosis, HIV or syphilis infections, as well as hepatitis B surface antigen positivity and/or hepatitis C PCR positivity verified at screening • Current immunomodulatory/immunosuppressive treatment • Immunomodulatory/immunosuppressive treatment within 6 months prior to inclusion. This includes, but is not restricted to treatment with natalizumab, fingolimod, dimetylfumurat, glatiramer acetate, interferon beta medications, teriflunomide, and siponimod. • Treatment with kladribin, ocrelizumab, rituximab, and alemtuzumab within 12 months prior to inclusion • Treatment with hematopoietic stem cell therapy within 12 months prior to inclusion • Treatment with glucocorticoids or ACTH within three months prior to start of inclusion • Having experienced an MS relapse within 2 years prior to study inclusion • History of malignancy other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year, within the last 10 years • Severely limited live expectancy by another co-morbid illness • History of previous diagnosis of myelodysplasia or previous hematologic disease (including lymphoproliferative disease, bone marrow insufficiency or previous lymphoid irradiation) or current clinically relevant abnormalities of white blood cell counts • Immunocompromised patients • Estimated glomerular filtration rate >60 ml/min/1.73 m2 or known renal failure • Bleeding or clotting diathesis or the use of antithrombotic or anticoagulative treatment • Platelet (thrombocyte) count < 100 x 10*9/L • Participation in another experimental clinical study with administration of another IMP within the preceding 12 months • Contraindications to MRI • Prior or current major depression • Prior or current psychiatric illness, mental deficiency or cognitive dysfunction influencing the patient ability to make an informed consent or comply with the treatment and follow-up phases of this protocol. • Pregnancy or risk of pregnancy (this includes patients that are unwilling to practice active contraception during the duration of the study), breastfeeding or lactation • Known hypersensitivity against paracetamol, codein or xylocain • Diagnosis or strong suspicion of polyneuropathy • Prior or current alcohol or drug dependencies • Inability to give informed consent |
|
E.5 End points |
E.5.1 | Primary end point(s) |
•Difference in combined evoked potentials (CEP; visual evoked potentials (VEP) + somatosensoric evoked potentials (SEP) + motor evoked potentials (MEP)) at 6 months (arm A vs. arm B) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Evaluation of number and nature of adverse events • Difference in CEP at 12 months (study treatment 1 vs. study treatment 2) • Difference in VEP at 6 months (arm A vs. arm B) • Difference in VEP at 12 months (study treatment 1 vs. study treatment 2) • Difference in SEP at 6 months (arm A vs. arm B) • Difference in SEP at 12 months (study treatment 1 vs. study treatment 2) • Difference in MEP at 6 months (arm A vs. arm B) • Difference in MEP at 12 months (study treatment 1 vs. study treatment 2) • Difference in EDSS at 6 months (arm A vs. arm B) • Difference in EDSS at 12 months (study treatment 1 vs. study treatment 2) • Difference in MRI T2-weighted hyperintense lesion volume at 6 months (arm A vs. arm B) • Difference in MRI T2-weighted hyperintense lesion volume at 12 months (study treatment 1 vs. study treatment 2) • Difference in MRI T1-weighted hypointense lesion volume at 6 months (arm A vs. arm B) • Difference in MRI T1-weighted hypointense lesion volume at 6 months (study treatment 1 vs. study treatment 2) • Difference in visual function (visual acuity, visual field, color vision and contrast sensitivity) at 6 months (arm A vs. arm B) • Difference in visual function (visual acuity, visual field, color vision and contrast sensitivity) at 12 months (study treatment 1 vs. study treatment 2) • Difference in retinal thickness measured with OCT at 6 months (arm A vs. arm B) • Difference in retinal thickness measured with OCT at 12 months (study treatment 1 vs study treatment 2) • Difference in brain volume at 6 months (arm A vs. arm B) • Difference in brain volume at 6 months (study treatment 1 vs. study treatment 2) • Difference in Nine-Hole-Peg Test (9-HPT) score at 6 months (arm A vs. arm B) • Difference in Nine-Hole-Peg Test (9-HPT) score at 6 months (study treatment 1 vs. study treatment 2) • Difference in Timed 25 Foot Walk (T25FW) score at 6 months (arm A vs. arm B) • Difference in Timed 25 Foot Walk (T25FW) score at 6 months (study treatment 1 vs. study treatment 2) • Difference in the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), European Quality of Life 5 dimensions (EQ-5D-5L), Multiple Sclerosis Impact Scale (MSIS) and Fatigue severity scale (FSS) score at 6 months (arm A vs. arm B) • Difference in the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), European Quality of Life 5 dimensions (EQ-5D-5L), Multiple Sclerosis Impact Scale (MSIS) and Fatigue severity scale (FSS) score at 12 months (study treatment 1 vs. study treatment 2) • Intraindividual CEP (longitudinal) between study treatment 1 vs. study treatment 2 in each patient
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |